Novo Nordisk ADR (NYSE: NVO)’s stock price has dropped by -2.52 in relation to previous closing price of 86.26. Nevertheless, the company has seen a loss of -4.07% in its stock price over the last five trading days. zacks.com reported 2025-01-13 that Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock’s prospects.
Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?
Novo Nordisk ADR (NYSE: NVO) has a higher price-to-earnings ratio of 27.27x compared to its average ratio. NVO has 36-month beta value of 0.45. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 1 as “sell.”
The public float for NVO is 3.34B, and currently, short sellers hold a 0.25% ratio of that float. The average trading volume of NVO on January 13, 2025 was 6.59M shares.
NVO’s Market Performance
NVO stock saw a decrease of -4.07% in the past week, with a monthly decline of -22.99% and a quarterly a decrease of -28.46%. The volatility ratio for the week is 1.69%, and the volatility levels for the last 30 days are 2.25% for Novo Nordisk ADR (NVO). The simple moving average for the past 20 days is -9.02% for NVO’s stock, with a -31.81% simple moving average for the past 200 days.
Analysts’ Opinion of NVO
Goldman, on the other hand, stated in their research note that they expect to see NVO reach a price target of $156. The rating they have provided for NVO stocks is “Buy” according to the report published on May 30th, 2024.
BMO Capital Markets gave a rating of “Outperform” to NVO, setting the target price at $163 in the report published on April 12th of the previous year.
NVO Trading at -17.13% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.24% of loss for the given period.
Volatility was left at 2.25%, however, over the last 30 days, the volatility rate increased by 1.69%, as shares sank -25.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.21% lower at present.
During the last 5 trading sessions, NVO fell by -4.45%, which changed the moving average for the period of 200-days by -35.28% in comparison to the 20-day moving average, which settled at $92.40. In addition, Novo Nordisk ADR saw -2.25% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.44 for the present operating margin
- 0.85 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.35. The total capital return value is set at 0.63. Equity return is now at value 88.20, with 26.99 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at 2.08. The debt to equity ratio resting at 0.47. The interest coverage ratio of the stock is 26.62.
Currently, EBITDA for the company is 113.33 billion with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 10.23. The receivables turnover for the company is 3.89for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.
Conclusion
To put it simply, Novo Nordisk ADR (NVO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
